Search Results - "MIGNARD, Dominique"

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study by TOURNIGAND, Christophe, ANDRE, Thierry, LANDI, Bruno, COLIN, Philippe, LOUVET, Christophe, DE GRAMONT, Aimery, ACHILLE, Emmanuel, LLEDO, Gérard, FLESH, Michel, MERY-MIGNARD, Dominique, QUINAUX, Emmanuel, COUTEAU, Corinne, BUYSE, Marc, GANEM, Gérard

“…In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination with irinotecan…”
Get full text

A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors by VASSAL, Gilles, DOZ, Francois, PEIN, Francois, FRAPPAZ, Didier, IMADALOU, Karima, SICARD, Evelyne, SANTOS, Alexandre, O'QUIGLEY, John, GERMA, Caroline, RISSE, Marie-Laure, MIGNARD, Dominique

“…A phase I study was performed to determine the maximum-tolerated dose (MTD) and safety profile of irinotecan (CPT-11) administered as a single intravenous…”
Get full text

Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients by BECOUARN, Yves, GAMELIN, Erick, BEKRADDA, Mohamed, MIGNARD, Dominique, MOUSSEAU, Mireille, COUDERT, Bruno, NEGRIER, Sylvie, PIERGA, Jean-Yves, RAOUL, Jean-Luc, PROVENCAL, Jocelyne, RIXE, Olivier, KRISCH, Claude, GERMA, Caroline

“…To assess antitumor activity and safety of two regimens in advanced colorectal cancer (CRC) patients with proven fluorouracil (5-FU) resistance in a randomized…”
Get full text

A Phase II study of irinotecan in patients with advanced renal cell carcinoma by Fizazi, Karim, Rolland, Frédéric, Chevreau, Christine, Droz, Jean‐Pierre, Mery‐Mignard, Dominique, Culine, Stéphane, Escudier, Bernard

“…BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy…”
Get full text

Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics by Wasserman, Ernesto, Cuvier, Caroline, Lokiec, François, Goldwasser, François, Kalla, Salima, Méry-Mignard, Dominique, Ouldkaci, Mahmoud, Besmaine, Amine, Dupont-André, Ghislaine, Mahjoubi, Mondher, Marty, Michel, Misset, Jean-Louis, Cvitkovic, Esteban

“…Two phase I studies of the oxaliplatin and irinotecan combination were performed in advanced gastrointestinal cancer patients to characterize the safety and…”
Get full text

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group Phase II Trial of First-Line Irinotecan in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Cervix by LHOMME, C, FUMOLEAU, P, LENTZ, M.-A, VAN GLABBEKE, M, MATTHIEU-BOUE, A, MIGNARD, D, CHEVALLIER, B, FARGEOT, P, KRAKOWSKI, Y, DIERAS, V, CHAUVERGNE, J, VENNIN, P, REBATTU, P, ROCHE, H, MISSET, J.-L

“…To determine the efficacy and tolerability of irinotecan (CPT-11) in advanced or recurrent cervical carcinoma. Eligible patients had histologically confirmed,…”
Get full text

Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer by DUCREUX, M, YCHOU, M, SEITZ, J.-F, BONNAY, M, BEXON, A, ARMAND, J.-P, MAHJOUBI, M, MERY-MIGNARD, D, ROUGIER, P

“…To determine the maximum-tolerated dose (MTD) and recommended dose of irinotecan (CPT-11) in combination with fluorouracil (5-FU) and leucovorin (LV), using a…”
Get full text

Circadian rhythm of irinotecan tolerability in mice by Filipski, Elisabeth, Lemaigre, Guy, Liu, Xu-Hui, Méry-Mignard, Dominique, Mahjoubi, Mondher, Lévi, Francis

“…The toxicity of irinotecan (CPT-11), a topoisomerase-I inhibitor largely used in cancer patients, was investigated as a function of the circadian time of its…”
Get more information

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study by Tournigand, Christophe, André, Thierry, Achille, Emmanuel, Lledo, Gérard, Flesh, Michel, Mery-Mignard, Dominique, Quinaux, Emmanuel, Couteau, Corinne, Buyse, Marc, Ganem, Gérard, Landi, Bruno, Colin, Philippe, Louvet, Christophe, de Gramont, Aimery

“…In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination with irinotecan…”
Get full text

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours by Soria, Jean Charles, Massard, Christophe, Lazar, Vladimir, Ozoux, Marie-Laure, Mery-Mignard, Dominique, Deslandes, Antoine, Tolcher, Anthony W

“…Abstract Purpose AVE1642, a humanised mAb, binds the human IGF-1R specifically and with high affinity. This study aimed to select the dose of AVE1642 alone and…”
Get full text

Abstract A134: Pharmacokinetics and metabolism of iniparib for the treatment of metastatic triple-negative breast cancer (TNBC) by Verweij, Jaap, Dieras, Veronique, Rockich, Kevin, Su, Yaming, Mery-Mignard, Dominique, Pham, Nga, Emmons, Gary

“…Abstract Background: Iniparib (BSI-201) is an investigational anticancer agent whose mechanism of action is under study. In breast cancer cell lines and…”
Get full text

High prognostic significance of residual disease after neoadjuvant chemotherapy : a retrospective study in 710 patients with operable breast cancer by AMAT, Sophie, ABRIAL, Catherine, CURE, Hervé, CHOLLET, Philippe, PENAULT-LLORCA, Frédérique, DELVA, Rémi, BOUGNOUX, Philippe, LEDUC, Bernard, MOURET-REYNIER, Marie-Ange, MERY-MIGNARD, Dominique, BLEUSE, Jean-Pierre, DAUPLAT, Jacques

“…Prognostic factors are used to help clinical decision-making in selecting the appropriate treatment for individual patients. The purpose of this retrospective…”
Get full text

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level by Boige, Valérie, Taïeb, Julien, Hebbar, Mohamed, Malka, David, Debaere, Thierry, Hannoun, Laurent, Magherini, Emmanuelle, Mignard, Dominique, Poynard, Thierry, Ducreux, Michel

“…This study assessed the clinical activity and safety of irinotecan (CPT-11) in patients with advanced hepatocellular carcinoma (HCC) using dose adjustment…”
Get full text

Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma by Moreau, Philippe, Hulin, Cyrille, Facon, Thierry, Boccadoro, Mario, Mery-Mignard, Dominique, Deslandes, Antoine, Harousseau, Jean-Luc

“…Rationale: CD221 (IGF-1R) is aberrantly expressed in multiple myeloma (MM) and is associated with disease severity (Bataille et al, Haematologica 2005;…”
Get full text

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment by Saliba, F, Hagipantelli, R, Misset, J L, Bastian, G, Vassal, G, Bonnay, M, Herait, P, Cote, C, Mahjoubi, M, Mignard, D, Cvitkovic, E

“…Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of…”
Get more information

High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer by Abrial, Sophie Catherine, Penault-Llorca, Frédérique, Delva, Rémi, Bougnoux, Philippe, Leduc, Bernard, Mouret-Reynier, Marie-Ange, Mery-Mignard, Dominique, Bleuse, Jean-Pierre, Dauplat, Jacques, Curé, Hervé, Chollet, Philippe

Get full text

Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents by Vassal, Gilles, Méry-Mignard, Dominique, Caulin, Charles

“…Childhood and adolescent cancers are rare diseases. Despite the progress in treatment (more than two-thirds of all cases are cured), cancer remains the leading…”
Get more information

Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer : An open-label multicenter phase II study by YCHOU, M, DOUILLARD, J. Y, ROUGIER, P, ADENIS, A, MOUSSEAU, M, DUFOUR, P, WENDLING, J. L, BURKI, F, MIGNARD, D, MARTY, M

“…Delayed diarrhea is the main toxicity of irinotecan at the currently recommended dose of 350 mg/m2 30-minute intravenous infusion, once every 3 weeks. This…”
Get full text